<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424619</url>
  </required_header>
  <id_info>
    <org_study_id>06-449</org_study_id>
    <secondary_id>P1975</secondary_id>
    <nct_id>NCT00424619</nct_id>
  </id_info>
  <brief_title>A Randomised, Controlled Comparison of Vitamin D Strategies is Acute Hip Fracture Patients</brief_title>
  <official_title>A Randomised, Controlled Comparison of Vitamin D Strategies is Acute Hip Fracture Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Frosst Canada Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the best dose of Vitamin D to give to hip fracture
      patients to achieve the optimal therapeutic level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low Vitamin D levels can cause faster bone loss and increase the risk of having a fracture.
      Patients who experience a hip fracture have low levels of Vitamin D. It is not clear how much
      Vitamin D must be taken in order to reach this optimal level.

      Serum 25-hydroxyvitamin D3 (25-OHD) concentrations are the recognized functional status
      indicator for vitamin D. Although there is no clear consensus, vitamin D 'insufficiency' has
      been considered in the range of 25- 75/80 nmol/L. Patients with acute hip fracture are at
      high risk for a recurrent hip fracture or other fragility fractures (and falls) and are a
      group who should be targeted for osteoporosis treatment (i.e. Bisphosphonate or other
      antiresorptive). Before fracture patients start on a bisphosphonate, however, an important
      consideration is whether 25-OHD levels are at a therapeutic level (&gt;75 nmol/l and less than
      150-200 nmol/L). Case-control studies indicate that older people who experience a hip
      fracture have lower serum concentrations of 25-OHD than do those without a fracture. In
      cross-sectional studies, the majority of patients with hip fracture are considered to have
      insufficient vitamin D levels. Although the benefits of supplementing patients with at least
      800 to 1000 IU/day Vitamin D3 may be recognized, there is little information available to
      guide physicians regarding the appropriate management of hip fracture patients who may be
      severely Vitamin D deficient, particularly in acute hip fracture patients. Few studies have
      examined whether high dose vitamin D (i.e. 50,000 IU or greater/week) offers an advantage
      over smaller, routinely prescribed doses (i.e. 800 or 1000 IU), particularly in hip fracture
      patients.

      The purpose of this study is to determine the number of hip fracture patients reaching an
      optimal level of vitamin D comparing between three different Vitamin D dose strategies:

      A. 50,000 D2 oral bolus followed by 800 IU D3 daily B. 100,000 D2 oral bolus followed by 800
      IU D3 daily C. 800 IU D3 daily

      The Vitamin D strategies will be administered over 3-months in acute hip fracture patients.
      The proportion of patients reaching an optimal level of 25-OHD (&gt;75 nmol/L) will be
      determined.

      Secondary measures include the Timed Up and Go test, and 2 Minute Walk Test to compare the
      effects of the Vitamin D supplementation strategies on functional and muscle strength scales.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>25-hydroxyvitamin D3 (25-OHD)</measure>
    <time_frame>Baseline, 4 weeks and 3 months</time_frame>
    <description>Serum 25-hydroxyvitamin D3 (25-OHD) was measured at baseline, at discharge from hospital (approximately 4-weeks), and at a follow-up study visit at approximately 3-months.Baseline and 4-week blood samples were drawn in-hospital; venipunctures performed at 3-months were either in-hospital (if patient remained in acute care or rehabilitation) or at the out-patient clinic visit.Serum 25-OHD was analyzed with the DiaSorin, 25-hydroxyvitamin D radioimmunoassay (Stillwater, Minnesota 55082-0285, U.S.A) at the central laboratory with the exception of 3 patients (data analyzed at other laboratories).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid Hormone (PTH)</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood samples were drawn in-hospital. In additional PTH was accessed at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcium</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Baseline blood samples were drawn in-hospital. In additional Calcium was accessed at baseline and approximately 4 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phosphate</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood samples were drawn in-hospital. In additional phosphate was accessed at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alkaline Phosphatase</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood samples were drawn in-hospital. In additional Alkaline Phosphatase was accessed at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood samples were drawn in-hospital. In additional hemoglobin was accessed at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline blood samples were drawn in-hospital. In additional creatinine was accessed at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment Using the Timed Up and Go (TUG) Test After 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>The Timed Up and Go (TUG) was collected for patients who attended the 3-month clinic appointment by study coordinators or for patients who attended the rehabilitation unit this is routinely collected and was abstracted from chart. The TUG was conducted using a standard armchair and a line marked 3-metres from the chair. Participants were given the following instructions (no physical assistance was given): &quot;Rise from the chair, walk to the line on the floor, turn, return to the chair and sit down again&quot;. Scores are measured as time in seconds to complete the task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment Using the Two Minute Walk Test (2MWT)After 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>The 2MWT was collected for patients who attended the 3-month clinic appointment by study coordinators or for patients who attended rehabilitation, it was abstracted from their charts. The 2MWT test was given in a carpeted corridor and the subject was instructed to wear regular footwear and to use their customary walking aid. The distance the participant could comfortably walk in two-minutes (without physical assistance) was measured in metres.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Hip Fracture</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 000 IU Vitamin D2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 000 IU Vitamin D2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D2</intervention_name>
    <description>50 000 IU vitamin D2, one time bolus dose</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ostoforte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D2</intervention_name>
    <description>100 000 IU vitamin D2, one time bolus dose</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Ostoforte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 1 time bolus dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fragility hip fracture patient

          -  Previous Vitamin D supplementation is okay.

        Exclusion Criteria:

          -  Patients with pathological fracture secondary to malignancy or intrinsic bone disease
             (eg. Paget's disease)

          -  Cancer in the past 10 years likely to metastasize to bone

          -  Renal insufficiency (creatinine &lt;30 mls/min)

          -  Hypercalcemia (primary hyperparathyroidism; granulomatous diseases; drug-induced such
             as lithium, thiazides), hypocalcemia, hypercalciuria, fracture or stroke within the
             last 3 months

          -  Hormone replacement therapy, calcitonin, fluoride, or bisphosphonates during the
             previous 24 months

          -  Pre-existing bone abnormality

          -  Renal stones in past 10 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Papaioannou, M.D., M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2007</study_first_submitted>
  <study_first_submitted_qc>January 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2007</study_first_posted>
  <results_first_submitted>July 25, 2011</results_first_submitted>
  <results_first_submitted_qc>May 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 14, 2012</results_first_posted>
  <last_update_submitted>May 11, 2012</last_update_submitted>
  <last_update_submitted_qc>May 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Alexandra Papaioannou</investigator_full_name>
    <investigator_title>Dr. Alexandra Papaioannou</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Hip fracture</keyword>
  <keyword>Optimal level</keyword>
  <keyword>Deficiency</keyword>
  <keyword>Functional muscle strength</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>50 000 IU Vitamin D2</title>
          <description>50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
        </group>
        <group group_id="P2">
          <title>100 000 IU Vitamin D2</title>
          <description>100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo at beginning of study and 1000IU vitamin D3 for 90 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="21">n=21 but one participant was lost as a screen failure</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>4 Week</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>3 Month</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>50 000 IU Vitamin D2</title>
          <description>50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
        </group>
        <group group_id="B2">
          <title>100 000 IU Vitamin D2</title>
          <description>100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo at beginning of study and 1000IU vitamin D3 for 90 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.9" spread="8.7"/>
                    <measurement group_id="B2" value="73.9" spread="12.4"/>
                    <measurement group_id="B3" value="78.5" spread="10.3"/>
                    <measurement group_id="B4" value="78.43" spread="11.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment Using the Timed Up and Go (TUG) Test After 3 Months</title>
        <description>The Timed Up and Go (TUG) was collected for patients who attended the 3-month clinic appointment by study coordinators or for patients who attended the rehabilitation unit this is routinely collected and was abstracted from chart. The TUG was conducted using a standard armchair and a line marked 3-metres from the chair. Participants were given the following instructions (no physical assistance was given): “Rise from the chair, walk to the line on the floor, turn, return to the chair and sit down again”. Scores are measured as time in seconds to complete the task.</description>
        <time_frame>3 months</time_frame>
        <population>The number of participants who completed the TUG test is lower than the number of participants who completed the primary outcome at this time point. Not everyone chose to complete the functional TUG test at this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>50 000 IU Vitamin D2</title>
            <description>50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O2">
            <title>100 000 IU Vitamin D2</title>
            <description>100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment Using the Timed Up and Go (TUG) Test After 3 Months</title>
          <description>The Timed Up and Go (TUG) was collected for patients who attended the 3-month clinic appointment by study coordinators or for patients who attended the rehabilitation unit this is routinely collected and was abstracted from chart. The TUG was conducted using a standard armchair and a line marked 3-metres from the chair. Participants were given the following instructions (no physical assistance was given): “Rise from the chair, walk to the line on the floor, turn, return to the chair and sit down again”. Scores are measured as time in seconds to complete the task.</description>
          <population>The number of participants who completed the TUG test is lower than the number of participants who completed the primary outcome at this time point. Not everyone chose to complete the functional TUG test at this time point.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" lower_limit="19.2" upper_limit="33.2"/>
                    <measurement group_id="O2" value="19.1" lower_limit="14.1" upper_limit="24.1"/>
                    <measurement group_id="O3" value="18.1" lower_limit="12.4" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>25-hydroxyvitamin D3 (25-OHD)</title>
        <description>Serum 25-hydroxyvitamin D3 (25-OHD) was measured at baseline, at discharge from hospital (approximately 4-weeks), and at a follow-up study visit at approximately 3-months.Baseline and 4-week blood samples were drawn in-hospital; venipunctures performed at 3-months were either in-hospital (if patient remained in acute care or rehabilitation) or at the out-patient clinic visit.Serum 25-OHD was analyzed with the DiaSorin, 25-hydroxyvitamin D radioimmunoassay (Stillwater, Minnesota 55082-0285, U.S.A) at the central laboratory with the exception of 3 patients (data analyzed at other laboratories).</description>
        <time_frame>Baseline, 4 weeks and 3 months</time_frame>
        <population>Baseline data (n=59) was missing for two participants, and four outliers with 25-OHD taken at 6, 10 or 12 days were not included. 4-week data (n=50) was missing for 13 participants, and two outliers with 25-OHD taken at &lt;13 days were not included. 3-month data (n=47) was missing for 18 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>50 000 IU Vitamin D2</title>
            <description>50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O2">
            <title>100 000 IU Vitamin D2</title>
            <description>100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>25-hydroxyvitamin D3 (25-OHD)</title>
          <description>Serum 25-hydroxyvitamin D3 (25-OHD) was measured at baseline, at discharge from hospital (approximately 4-weeks), and at a follow-up study visit at approximately 3-months.Baseline and 4-week blood samples were drawn in-hospital; venipunctures performed at 3-months were either in-hospital (if patient remained in acute care or rehabilitation) or at the out-patient clinic visit.Serum 25-OHD was analyzed with the DiaSorin, 25-hydroxyvitamin D radioimmunoassay (Stillwater, Minnesota 55082-0285, U.S.A) at the central laboratory with the exception of 3 patients (data analyzed at other laboratories).</description>
          <population>Baseline data (n=59) was missing for two participants, and four outliers with 25-OHD taken at 6, 10 or 12 days were not included. 4-week data (n=50) was missing for 13 participants, and two outliers with 25-OHD taken at &lt;13 days were not included. 3-month data (n=47) was missing for 18 participants.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5" spread="34.8-58.6" lower_limit="42.3" upper_limit="64.8"/>
                    <measurement group_id="O2" value="58.4" lower_limit="47.3" upper_limit="69.5"/>
                    <measurement group_id="O3" value="46.7" lower_limit="34.8" upper_limit="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" lower_limit="73.7" upper_limit="95.3"/>
                    <measurement group_id="O2" value="75.6" lower_limit="64.5" upper_limit="86.8"/>
                    <measurement group_id="O3" value="69.3" lower_limit="58.4" upper_limit="80.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" lower_limit="73.6" upper_limit="94.9"/>
                    <measurement group_id="O2" value="73.3" lower_limit="64.5" upper_limit="82.1"/>
                    <measurement group_id="O3" value="86.7" lower_limit="77.6" upper_limit="95.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parathyroid Hormone (PTH)</title>
        <description>Baseline blood samples were drawn in-hospital. In additional PTH was accessed at baseline.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 000 IU Vitamin D2</title>
            <description>50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O2">
            <title>100 000 IU Vitamin D2</title>
            <description>100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone (PTH)</title>
          <description>Baseline blood samples were drawn in-hospital. In additional PTH was accessed at baseline.</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.35" spread="3.01"/>
                    <measurement group_id="O2" value="5.10" spread="3.91"/>
                    <measurement group_id="O3" value="4.2" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Calcium</title>
        <description>Baseline blood samples were drawn in-hospital. In additional Calcium was accessed at baseline and approximately 4 weeks.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 000 IU Vitamin D2</title>
            <description>50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O2">
            <title>100 000 IU Vitamin D2</title>
            <description>100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Calcium</title>
          <description>Baseline blood samples were drawn in-hospital. In additional Calcium was accessed at baseline and approximately 4 weeks.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10" spread="0.14"/>
                    <measurement group_id="O2" value="2.12" spread="0.11"/>
                    <measurement group_id="O3" value="2.08" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="0.17"/>
                    <measurement group_id="O2" value="2.31" spread="0.11"/>
                    <measurement group_id="O3" value="2.28" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phosphate</title>
        <description>Baseline blood samples were drawn in-hospital. In additional phosphate was accessed at baseline.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 000 IU Vitamin D2</title>
            <description>50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O2">
            <title>100 000 IU Vitamin D2</title>
            <description>100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Phosphate</title>
          <description>Baseline blood samples were drawn in-hospital. In additional phosphate was accessed at baseline.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.22"/>
                    <measurement group_id="O2" value="0.97" spread="0.24"/>
                    <measurement group_id="O3" value="0.94" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Alkaline Phosphatase</title>
        <description>Baseline blood samples were drawn in-hospital. In additional Alkaline Phosphatase was accessed at baseline.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 000 IU Vitamin D2</title>
            <description>50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O2">
            <title>100 000 IU Vitamin D2</title>
            <description>100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Alkaline Phosphatase</title>
          <description>Baseline blood samples were drawn in-hospital. In additional Alkaline Phosphatase was accessed at baseline.</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" spread="3.78"/>
                    <measurement group_id="O2" value="78.7" spread="26.2"/>
                    <measurement group_id="O3" value="79.4" spread="51.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin</title>
        <description>Baseline blood samples were drawn in-hospital. In additional hemoglobin was accessed at baseline.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 000 IU Vitamin D2</title>
            <description>50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O2">
            <title>100 000 IU Vitamin D2</title>
            <description>100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin</title>
          <description>Baseline blood samples were drawn in-hospital. In additional hemoglobin was accessed at baseline.</description>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.2" spread="14.3"/>
                    <measurement group_id="O2" value="107.9" spread="17.4"/>
                    <measurement group_id="O3" value="108.6" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Creatinine</title>
        <description>Baseline blood samples were drawn in-hospital. In additional creatinine was accessed at baseline.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 000 IU Vitamin D2</title>
            <description>50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O2">
            <title>100 000 IU Vitamin D2</title>
            <description>100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine</title>
          <description>Baseline blood samples were drawn in-hospital. In additional creatinine was accessed at baseline.</description>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" spread="23.8"/>
                    <measurement group_id="O2" value="77.4" spread="26.1"/>
                    <measurement group_id="O3" value="73.7" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment Using the Two Minute Walk Test (2MWT)After 3 Months</title>
        <description>The 2MWT was collected for patients who attended the 3-month clinic appointment by study coordinators or for patients who attended rehabilitation, it was abstracted from their charts. The 2MWT test was given in a carpeted corridor and the subject was instructed to wear regular footwear and to use their customary walking aid. The distance the participant could comfortably walk in two-minutes (without physical assistance) was measured in metres.</description>
        <time_frame>3 months</time_frame>
        <population>The number of participants who completed the 2WT is lower than the number of participants who completed the primary outcome at this time point. Not everyone chose to complete the functional 2WT test at this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>50 000 IU Vitamin D2</title>
            <description>50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O2">
            <title>100 000 IU Vitamin D2</title>
            <description>100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo at beginning of study and 1000IU vitamin D3 for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment Using the Two Minute Walk Test (2MWT)After 3 Months</title>
          <description>The 2MWT was collected for patients who attended the 3-month clinic appointment by study coordinators or for patients who attended rehabilitation, it was abstracted from their charts. The 2MWT test was given in a carpeted corridor and the subject was instructed to wear regular footwear and to use their customary walking aid. The distance the participant could comfortably walk in two-minutes (without physical assistance) was measured in metres.</description>
          <population>The number of participants who completed the 2WT is lower than the number of participants who completed the primary outcome at this time point. Not everyone chose to complete the functional 2WT test at this time point.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2" lower_limit="41.2" upper_limit="79.1"/>
                    <measurement group_id="O2" value="80.3" lower_limit="65.2" upper_limit="95.5"/>
                    <measurement group_id="O3" value="63.4" lower_limit="45.4" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>50 000 IU Vitamin D2</title>
          <description>50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
        </group>
        <group group_id="E2">
          <title>100 000 IU Vitamin D2</title>
          <description>100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo at beginning of study and 1000IU vitamin D3 for 90 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>fractured hip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>gangrenous left foot requiring amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary edmea and Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal Distention, nausea, vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Trip and fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alexandra Papaioannou</name_or_title>
      <organization>McMaster University</organization>
      <phone>905-521-2100 ext 77715</phone>
      <email>papaioannou@hhsc.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

